1. Home
  2. Labeler Index
  3. Northwind Pharmaceuticals
  4. 51655-832
  5. Product Images: Tamsulosin Hydrochloride

Product Images Tamsulosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Tamsulosin Hydrochloride NDC 51655-832 by Northwind Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - 51655 832 52 Master Bottle Label Approval Rev A 02 22

Label - 51655 832 52 Master Bottle Label Approval Rev A 02 22

This is a prescription medicine called Tamsulosin Hydrochloride Capsules, USP 0.4mg with NDC number 51655-832-52. It comes in 30 capsules and should be stored at room temperature. The capsule contains Tamsulosin Hydrochloride USP 0.4mg. The medicine is repackaged by Northwind Pharmaceticals from Aurobindo Pharma USA, Inc., Lot 0000000000. The GTIN is 0035165832523, the S/N is 000000000000000. The expiration date is 00/00/0000 and the lot number is 0000000000. It is important to keep the medicine out of reach of children and store in the original container to avoid excessive moisture. Please see package insert for dosage information.*

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

This appears to be a figure with a graph showing the mean plasma concentrations of Tamsulosin Hydrochloride after being administered a single dose of 0.4mg under fasted and fed conditions. The graph shows the concentrations at different time intervals (in hours) for both fasted and fed conditions. No further information is available from this text.*

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

The image displays a graph labeled 'Figure 3A' that describes the average increase in peak urine flow rate in L/Sec in Study 1. The graph compares three treatment options: 0.08mg, A=2x 0.4mg, and placebo. The x-axis shows the duration of treatment in weeks, and the y-axis shows the mean change in mL/sec. The graph shows that both the treatment options yield a higher mean change in mL/sec than the placebo. The number of participants in each group is given in parentheses next to each data point.*

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Chemical Structure - tamsulosin str

Chemical Structure - tamsulosin str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.